The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants.
Chi-Kuei HsuWan-Hsuan HsuBo-Wen ShiauYa-Wen TsaiJheng-Yen WuTing-Hui LiuPo-Yu HuangMin-Hsiang ChuangChih-Cheng LaiPublished in: Expert review of anti-infective therapy (2024)
The use of novel oral antiviral including NMV-r or MOV can be associated with a lower risk of all-cause hospitalization, or death in non-hospitalized high-risk patients with COVID-19 during Omicron XBB wave.